Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Chunyou Wang

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5074753954. Sources: OpenAlex.

Their work

Papers
54 (first author 2, last author 18)
Trials
0
Grants
0
Labs led
1
Collaborators
102
Papers, trials and grants by year

2011: 3 papers · 2012: 4 papers · 2013: 7 papers · 2014: 5 papers · 2015: 3 papers · 2016: 9 papers · 2017: 4 papers · 2018: 5 papers · 2019: 5 papers · 2020: 3 papers · 2021: 3 papers · 2022: none · 2023: 2 papers · 2024: none · 2025: 1 paper

Papers 50 of 54

  1. Retraction: MiR-744 increases tumorigenicity of pancreatic cancer by activating Wnt/β-catenin pathway. Co-author DOI 10.18632/oncotarget.28806↗
  2. Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreati… Co-author DOI 10.1186/s13578-023-01155-8↗
  3. Clinical-radiomics nomogram using contrast-enhanced CT to predict histological grade and survival in pancreatic ductal adenocarcinoma. First author DOI 10.3389/fonc.2023.1218128↗
  4. Hypoxic exosomal HIF-1α-stabilizing circZNF91 promotes chemoresistance of normoxic pancreatic cancer cells via enhancing glycolysis. Co-author DOI 10.1038/s41388-021-01960-w↗
  5. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway. Co-author DOI 10.1158/0008-5472.can-21-0281↗
  6. Pancreatic Ductal Adenocarcinoma at CT: A Combined Nomogram Model to Preoperatively Predict Cancer Stage and Survival Outcome. Co-author DOI 10.3389/fonc.2021.594510↗
  7. Long noncoding RNA ITGB2-AS1 promotes growth and metastasis through miR-4319/RAF1 axis in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/jcp.29471↗
  8. LncRNA differentiation antagonizing non-protein coding RNA promotes proliferation and invasion through regulating miR-135a/NLRP37 axis in pancreatic cancer. Co-author DOI 10.1007/s10637-019-00798-0↗
  9. A reciprocal feedback of Myc and lncRNA MTSS1-AS contributes to extracellular acidity-promoted metastasis of pancreatic cancer. Co-author DOI 10.7150/thno.49147↗
  10. ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer. Co-author DOI 10.1016/j.omto.2019.07.005↗
  11. Nutrient Stress-Dysregulated Antisense lncRNA GLS-AS Impairs GLS-Mediated Metabolism and Represses Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-18-0419↗
  12. High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway. Co-author DOI 10.1186/s13046-019-1209-9↗
  13. Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cel… Co-author DOI 10.1186/s13578-019-0312-0↗
  14. LncRNA-MTA2TR functions as a promoter in pancreatic cancer via driving deacetylation-dependent accumulation of HIF-1α. Co-author DOI 10.7150/thno.34559↗
  15. Overexpression of MIST1 reverses the epithelial-mesenchymal transition and reduces the tumorigenicity of pancreatic cancer cells via the Snail/E-cadherin pathw… Last author DOI 10.1016/j.canlet.2018.05.043↗
  16. Impact of age on survival of patients with pancreatic cancer after surgery: Analysis of SEER data. Last author DOI 10.1016/j.pan.2017.11.008↗
  17. MiRNA-646-mediated reciprocal repression between HIF-1α and MIIP contributes to tumorigenesis of pancreatic cancer. Co-author DOI 10.1038/s41388-017-0082-2↗
  18. Hypoxia-induced LncRNA-BX111 promotes metastasis and progression of pancreatic cancer through regulating ZEB1 transcription. Co-author DOI 10.1038/s41388-018-0382-1↗
  19. The responsively decreased PKM2 facilitates the survival of pancreatic cancer cells in hypoglucose. Co-author DOI 10.1038/s41419-017-0158-5↗
  20. ASIC1 and ASIC3 contribute to acidity-induced EMT of pancreatic cancer through activating Ca2+/RhoA pathway. Co-author DOI 10.1038/cddis.2017.189↗
  21. Centrosomal protein 55 activates NF-κB signalling and promotes pancreatic cancer cells aggressiveness. Co-author DOI 10.1038/s41598-017-06132-z↗
  22. The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis. Last author DOI 10.1038/s41598-017-06207-x↗
  23. Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells. Co-author DOI 10.1111/jcmm.13126↗
  24. Implantation of radioactive (125)I seeds improves the prognosis of locally advanced pancreatic cancer patients: A retrospective study. Co-author DOI 10.1007/s11596-016-1567-x↗
  25. Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade. Co-author DOI 10.1016/j.canlet.2016.08.023↗
  26. Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. Co-author DOI 10.1038/ng.3568↗
  27. Plasma miRNAs Effectively Distinguish Patients With Pancreatic Cancer From Controls: A Multicenter Study. Co-author DOI 10.1097/sla.0000000000001345↗
  28. MiR-548an, Transcriptionally Downregulated by HIF1α/HDAC1, Suppresses Tumorigenesis of Pancreatic Cancer by Targeting Vimentin Expression. Co-author DOI 10.1158/1535-7163.mct-15-0877↗
  29. Hypoxia-induced lncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by derepressing the miR-3923/KRAS pathway. Co-author DOI 10.18632/oncotarget.6830↗
  30. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3. Co-author DOI 10.18632/oncotarget.7482↗
  31. Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine. Last author DOI 10.18632/oncotarget.9293↗
  32. Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study. Co-author DOI 10.18632/oncotarget.9491↗
  33. Mutations in the p16 gene in DMBA-induced pancreatic intraepithelial neoplasia and pancreatic cancer in rats. Last author DOI 10.1016/s1499-3872(15)60331-9↗
  34. MiR-744 increases tumorigenicity of pancreatic cancer by activating Wnt/β-catenin pathway. Co-author DOI 10.18632/oncotarget.5317↗
  35. MiR-652 inhibits acidic microenvironment-induced epithelial-mesenchymal transition of pancreatic cancer cells by targeting ZEB1. Co-author DOI 10.18632/oncotarget.5350↗
  36. Oncogenicity of LHX2 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s11033-014-3716-2↗
  37. Chronic pancreatitis and pancreatic cancer demonstrate active epithelial-mesenchymal transition profile, regulated by miR-217-SIRT1 pathway. Co-author DOI 10.1016/j.canlet.2014.08.007↗
  38. Sirtuin 1 facilitates chemoresistance of pancreatic cancer cells by regulating adaptive response to chemotherapy-induced stress. Co-author DOI 10.1111/cas.12364↗
  39. Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway. Last author DOI 10.1186/1471-2407-14-370↗
  40. Dendritic cells loaded with pancreatic Cancer Stem Cells (CSCs) lysates induce antitumor immune killing effect in vitro. Last author DOI 10.1371/journal.pone.0114581↗
  41. Nicotinamide prohibits proliferation and enhances chemosensitivity of pancreatic cancer cells through deregulating SIRT1 and Ras/Akt pathways. Last author DOI 10.1016/j.pan.2013.01.001↗
  42. miR-148b functions as a tumor suppressor in pancreatic cancer by targeting AMPKα1. Last author DOI 10.1158/1535-7163.mct-12-0534-t↗
  43. miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4. Last author DOI 10.1158/1535-7163.mct-13-0296↗
  44. Hypermethylation of HIC1 promoter and aberrant expression of HIC1/SIRT1 might contribute to the carcinogenesis of pancreatic cancer. Last author DOI 10.1245/s10434-012-2364-9↗
  45. Low concentrations of metformin selectively inhibit CD133⁺ cell proliferation in pancreatic cancer and have anticancer action. Last author DOI 10.1371/journal.pone.0063969↗
  46. MiR-130b is a prognostic marker and inhibits cell proliferation and invasion in pancreatic cancer through targeting STAT3. Last author DOI 10.1371/journal.pone.0073803↗
  47. [Effect of buqi tongluo jiedu recipe on HIC1 methylation level of pancreatic cancer model mice]. First author PMID 24063222↗
  48. ShRNA silencing glycogen synthase kinase-3 beta inhibits tumor growth and angiogenesis in pancreatic cancer. Last author DOI 10.1016/j.canlet.2011.10.033↗
  49. Hypoxia-inducible factor-1 up-regulates the expression of Toll-like receptor 4 in pancreatic cancer cells under hypoxic conditions. Co-author DOI 10.1016/j.pan.2012.02.015↗
  50. Copy number variation at 6q13 functions as a long-range regulator and is associated with pancreatic cancer risk. Co-author DOI 10.1093/carcin/bgr228↗

Closest collaborators

The 25 strongest of 102 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Heshui Wu · 16 shared papers, 2011–2023 · strength 1.33
  2. Shanmiao Gou · 14 shared papers, 2011–2025 · strength 1.04
  3. Gang Zhao · 18 shared papers, 2013–2021 · strength 1.00
  4. Tao Yin · 13 shared papers, 2011–2023 · strength 0.91
  5. Shichang Deng · 14 shared papers, 2013–2019 · strength 0.70
  6. Qingke Duan · 7 shared papers, 2016–2023 · strength 0.67
  7. Shuai Zhu · 10 shared papers, 2013–2021 · strength 0.61
  8. Ye Zeng · 7 shared papers, 2018–2021 · strength 0.60
  9. Zhengle Zhang · 6 shared papers, 2016–2023 · strength 0.58
  10. Shi-Jiang Deng · 9 shared papers, 2014–2019 · strength 0.56
  11. Qi Qin · 9 shared papers, 2013–2020 · strength 0.55
  12. Hehe Li · 5 shared papers, 2017–2023 · strength 0.55
  13. Zhu Zeng · 7 shared papers, 2016–2021 · strength 0.53
  14. Fengyu Xu · 6 shared papers, 2018–2021 · strength 0.53
  15. Shihong Wu · 4 shared papers, 2019–2023 · strength 0.48
  16. Xiang Li · 9 shared papers, 2013–2018 · strength 0.44
  17. Mingliang Liu · 6 shared papers, 2016–2019 · strength 0.42
  18. Zhiqiang Liu · 5 shared papers, 2016–2018 · strength 0.42
  19. Hengqiang Zhao · 5 shared papers, 2016–2019 · strength 0.39
  20. Yuhang Hu · 4 shared papers, 2019–2021 · strength 0.38
  21. Haijiao Yan · 2 shared papers, 2015–2025 · strength 0.32
  22. Chunyuan Cen · 2 shared papers, 2021–2023 · strength 0.29
  23. Ping Han · 2 shared papers, 2021–2023 · strength 0.29
  24. Xiaogang Li · 3 shared papers, 2017–2018 · strength 0.29
  25. Yan Jin · 5 shared papers, 2014–2018 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.